Jeffrey Lewis joins Fried Frank
Managing IP is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2023

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Jeffrey Lewis joins Fried Frank

Jeffrey Lewis has joined Fried Frank Harris Shriver & Jacobson as a partner in the intellectual property litigation practice in New York


Lewis was previously partner at Patterson Belknap Webb & Tyler. He is a past president of the American Intellectual Property Law Association (AIPLA) and a fellow of the AIPLA and the American Bar Foundation.

Lewis concentrates on patent litigation but also handles trade mark matters, as well as other intellectual property and general litigation. He represents both plaintiffs and defendants in a range of technology-related sectors, focusing primarily on pharmaceuticals, chemicals, biotechnology and life sciences.

more from across site and ros bottom lb

More from across our site

Important dates for the Women in Business Law Awards for 2024 revealed
Each week Managing IP speaks to a different IP lawyer about their life and career
Negrão is the executive director of the EUIPO in Alicante
Mrs Justice Joanna Smith identified inconsistencies between evidence given by Stability AI’s CEO and comments he made in the media
The Chongqing First Intermediate People’s Court ruled Oppo must pay for the entire unlicensed period it used the Finnish company’s technology
Firms explain how monitoring, referrals and relationships with foreign firms helped them get more work at the TTAB
Luke Toft explains why he moved back to Fox Rothschild after working in-house at Sleep Number for five months
We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP
In a seminal ruling, the Beijing Internet Court said images generated by Stable Diffusion counted as original works
Boston-based John Lanza is hoping to work more with life sciences colleagues on the ‘exciting’ application of AI to drug discovery